Araştırma Makalesi
BibTex RIS Kaynak Göster

Yıl 2022, , 17 - 21, 30.03.2022

Ayşe Hümeyra Taşkın Kafa , Rukiye Aslan

https://doi.org/10.7197/cmj.1064847

Öz

Kaynakça

  • 1. Taylor TA, Unakal CG, Staphylococcus aureus. In: StatPearls. Treasure Island: StatPearls Publishing; 2021.
  • 2. Vuong C, Yeh AY, Cheung GY, Otto M. Investigational drugs to teart methicillin-resistant Staphylococcus aureus. Expert. Opin. Investig. Drugs 2015; 4: 1-21.
  • 3. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler Jr VG. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 2015; 28(3): 603-61.
  • 4. Bush K. Proliferation and significance of clinically relevant β‐lactamases. Annals of the New York Academy of Sciences 2013; 1277(1): 84-90.
  • 5. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339(8): 530-32.
  • 6. Chong YP, Park SJ, Bang KM, Kim SH, Lee SO, Choi SH, et al. Prevalence of blaZ gene types and the cefazolin inoculum effect among methicillin‐susceptible Staphylococcus aureus blood isolates and their association with multilocus sequence types and clinical outcome. Eur J Clin Microbiol Infect Dis 2015; 34(2): 349-55.
  • 7. Cushman DW, Ondetti MA. Design of angiotensin converting enzyme inhibitors. Nature Medicine 1999; 5(10): 1110-1112.
  • 8. Yusof Y, Tan D, Arjomandi O, Schenk G, McGeary R. Captopril analogues as metallo-β-lactamase inhibitors. Bioorg Med Chem Lett 2016; 26: 1589-1593.
  • 9. Dutta D, Mishra S. L-Captopril and its derivatives as potential inhibitors of microbial enzyme DapE: a combined approach of drug repurposing and similarity screening. J Mol Graph Model 2018; 84: 82-89.
  • 10. Eloff, JN. A Sensitive and quick microplate method to determine the minimal inhibitory concentration of plant extracts for bacteria Planta Med 1998; 64: 711-713.
  • 11. Man A, Santacroce L, Jacob R, Mare A, Man L. Antimicrobial activity of six essential oils against a group of human pathogenes: a comparative study. Pathogens 2009; 8(1): 15.
  • 12. Balouiri M, Sadiki M, Ibnsouda SK. Methods for in vitro evaluating antimicrobial activity: a review. J Pharm Anal 2016; 6(2): 71-79.
  • 13. Pillai SK, Moellering R, Eliopoulus GR. Antimicrobial combinations in: Lorian V (ed) Antibiotics in laboratıry medicine, Lippincott Williams and Wilkins, Philadelphia. 2005: 365-440.
  • 14. Frantini F, Mancini S, Turchi B, et al. A novel interpretation of the fractional inhibitory concentration index: the case Origanum vulgare L. and Leptospermum scoparium JR et G forst essential oils against staphylococcus aureus strains. Microbiological Research 2017; 195: 11-17.
  • 15. Gillner D, Armoush N, Holz RC, Becker DP. Inhibitors of bacterial N-succinyl-L, L-diaminopimelic acid desuccinylase (DapE) and demonstration of in vitro antimicrobial activity. Bioorganic & Medicinal Chemistry Letters 2009; 19(22): 6350-6352.
  • 16. Heinz U, Bauer R, Wommer S, Meyer-Klaucke W, Papamicael C, Bateson J, Aldoplh HW. Coordination geometries of metal ions in D- or L-captopril-inhibited metallo- β -lactamase. J Biol Chem 2003; 278: 20659-20666.
  • 17. Crcek M, Zdovc J, Kerec Kos MA. A review of population pharmacokinetic models of gentamicin in paediatric patients. J Clin Pharm Ther 2019; 44: 659-674.
  • 18. Wargo KA, Edwards JD. Aminoglycoside-induced nephrotoxicity. J Pharm Pract 2014; 27(6): 573-577.
  • 19. de Aguiar FC, Solarte AL, Tarradas C, Gómez-Gascón L, Astorga R, Maldonado A, Huerta B. Combined effect of conventional antimicrobials with essential oils and their main components against resistant Streptococcus suis strains. Lett Appl Microbiol. 2019;68(6):562-72.
  • 20. Ghafelehbeshi R, et al. Preparation, physicochemical properties, in vitro evaluation and release behavior of cephalexin-loaded niosomes. Int J Pharm 2019; 5: 569.
  • 21. Lopes E, et al. Epidemiology and antimicrobial resistance of methicillin-resistant Staphylococcus aureus isolates colonizing pigs with different exposure to antibiotics. Plos One 2019; 14(11): 1-10.
  • 22. Xu X, Xu L, Yuan G, Wang Y, Qu Y, Zhou M. Synergistic combination of two antimicrobial agents closing each other’s mutant selection windows to prevent antimicrobial resistance. Sci Rep 2018; 8: 7237-7243.
  • 23. Rahal JJ. Antibiotic combinations: the clinical relevance of synergy and antagonism. Medicine (Baltimore) 1978; 57: 179-195.
  • 24. Aaron SD, Ferris W, Henry DA. Speert DP, MacDonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000; 161: 1206-1212.
  • 25. Nicolas M, Vazquez GF, Paulo A, Caceres G, Silvia M. Carnosic acid acts synergistically with gentamicin in killing methicillin-resistant Staphylococcus aureus clinical isolates. Phytomedicine 2016; 23(12): 1337-1343.
  • 26. Paduszynska MA, Greber KE, Paduszynski W, Sawicki W, Kamysz W. Activity of temporin a and short lipopeptides combined with gentamicin against biofilm formed by Staphylococcusaureus and Pseudomonas aeruginosa. Antibiotics (Basel, Switzerland) 2020; 9(9): 566.
  • 27. Manoraj A, Theyanesam V, Bandara B, Ekanayake A, Liyanapathiana V. Synergistic activity between Triphala and selected antibiotics against drug resistant clinical isolates. BMC Complementary and Alternative Medicine 2019; 19(1): 199.
  • 28. Gil D, Daffine K, Friedman R, Bhushan B, Muratoglu OK, LaPlante K, Oral E. Synergistic antibacterial effects of analgesics and antibiotics against Staphylococcus aureus. Diagnostic Microbiology and Infectious Disease 2020; 96(4): 114967.
  • 29. Feldman M, Smoum R, Mechoulam R, Steinberg D. Potential combinations of endocannabinoid/endocannabinoid-like compounds and antibiotics against methicillin-resistant Staphylococcus aureus. Plos One 2020; 15(4): 1-13.
  • 30. Dall GF, Tsang S, Gwynne PJ, MacKenzie SP, Simpson A, Breusch SJ, Gallahger MP. Unexpected synergistic and antagonistic antibiotic activity against Staphylococcus biofilms. Journal of Antimicrobial Chemotheraphy 2018; 73(7): 1830-1840.
  • 31. Brem J, Berkel V, Zollman SS, Lee D, Gileadi SY, McHugh O, Walsh PJ, Walsh TR, McDonough MA, Schofield CJ. Structural basis of metallo-β-lactamase ınhibition by captopril stereoisomers, Antimicrobial Agents and Chemotheraphy 2015; 60(1): 142-150.

Antagonism Between Antibiotics Frequently Used in The Treatment of Staphylococcus aureus Infections and The Hypertensive Drug L-Captopril

Yıl 2022, , 17 - 21, 30.03.2022

Ayşe Hümeyra Taşkın Kafa , Rukiye Aslan

https://doi.org/10.7197/cmj.1064847

Öz

Objective: Captopril is a long-acting human angiotensin-converting enzyme (ACE) inhibitor that has been used to treat hypertension and heart failure for many years. In this study, it was aimed to determine the antimicrobial activity of L-captopril on Methicillin-Resistant Staphylococcus aureus MRSA and Methicillin-Sensitive Staphylococcus aureus (MSSA) clinical isolates and, demonstrate the combination activity of captopril with ciprofloxacin (CXP) and gentamicin (GEN), which are among antistaphylococcal chemical agents.
Method: The minimum inhibitor concentration (MIC) and minimum bactericidal concentration (MBC) were determined using the microdilution technique in 96-well microtiter plates. The activity of L-captopril and CXP or GEN combination against MRSA and MSSA clinical isolates was determined by the micro-broth checkerboard assay method.
Results: The captopril MIC value was determined to be 2.5 mg/ml in all bacteria strains tested. The captopril/CXP combination had an indifferent effect in the other strains tested except for one MRSA isolate. The captopril/GEN combination had an antagonistic effect in all strains studied and increased the MIC 2-4 fold. The captopril/GEN combination was found to reduce the bactericidal activity of gentamicin.
Conclusions: The study results suggest that exposure to these drugs may lead to multidrug resistance in S. aureus bacteria. Especially in the hypertensive patient group, the induced resistance in any S. aureus infections should be taken into consideration while using captopril and, it should be considered that this antagonism may cause an increase in S. aureus infections.

Anahtar Kelimeler

Captopril checkerboard ciprofloxacin gentamicin staphylococcus aureus

Kaynakça

  • 1. Taylor TA, Unakal CG, Staphylococcus aureus. In: StatPearls. Treasure Island: StatPearls Publishing; 2021.
  • 2. Vuong C, Yeh AY, Cheung GY, Otto M. Investigational drugs to teart methicillin-resistant Staphylococcus aureus. Expert. Opin. Investig. Drugs 2015; 4: 1-21.
  • 3. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler Jr VG. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 2015; 28(3): 603-61.
  • 4. Bush K. Proliferation and significance of clinically relevant β‐lactamases. Annals of the New York Academy of Sciences 2013; 1277(1): 84-90.
  • 5. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339(8): 530-32.
  • 6. Chong YP, Park SJ, Bang KM, Kim SH, Lee SO, Choi SH, et al. Prevalence of blaZ gene types and the cefazolin inoculum effect among methicillin‐susceptible Staphylococcus aureus blood isolates and their association with multilocus sequence types and clinical outcome. Eur J Clin Microbiol Infect Dis 2015; 34(2): 349-55.
  • 7. Cushman DW, Ondetti MA. Design of angiotensin converting enzyme inhibitors. Nature Medicine 1999; 5(10): 1110-1112.
  • 8. Yusof Y, Tan D, Arjomandi O, Schenk G, McGeary R. Captopril analogues as metallo-β-lactamase inhibitors. Bioorg Med Chem Lett 2016; 26: 1589-1593.
  • 9. Dutta D, Mishra S. L-Captopril and its derivatives as potential inhibitors of microbial enzyme DapE: a combined approach of drug repurposing and similarity screening. J Mol Graph Model 2018; 84: 82-89.
  • 10. Eloff, JN. A Sensitive and quick microplate method to determine the minimal inhibitory concentration of plant extracts for bacteria Planta Med 1998; 64: 711-713.
  • 11. Man A, Santacroce L, Jacob R, Mare A, Man L. Antimicrobial activity of six essential oils against a group of human pathogenes: a comparative study. Pathogens 2009; 8(1): 15.
  • 12. Balouiri M, Sadiki M, Ibnsouda SK. Methods for in vitro evaluating antimicrobial activity: a review. J Pharm Anal 2016; 6(2): 71-79.
  • 13. Pillai SK, Moellering R, Eliopoulus GR. Antimicrobial combinations in: Lorian V (ed) Antibiotics in laboratıry medicine, Lippincott Williams and Wilkins, Philadelphia. 2005: 365-440.
  • 14. Frantini F, Mancini S, Turchi B, et al. A novel interpretation of the fractional inhibitory concentration index: the case Origanum vulgare L. and Leptospermum scoparium JR et G forst essential oils against staphylococcus aureus strains. Microbiological Research 2017; 195: 11-17.
  • 15. Gillner D, Armoush N, Holz RC, Becker DP. Inhibitors of bacterial N-succinyl-L, L-diaminopimelic acid desuccinylase (DapE) and demonstration of in vitro antimicrobial activity. Bioorganic & Medicinal Chemistry Letters 2009; 19(22): 6350-6352.
  • 16. Heinz U, Bauer R, Wommer S, Meyer-Klaucke W, Papamicael C, Bateson J, Aldoplh HW. Coordination geometries of metal ions in D- or L-captopril-inhibited metallo- β -lactamase. J Biol Chem 2003; 278: 20659-20666.
  • 17. Crcek M, Zdovc J, Kerec Kos MA. A review of population pharmacokinetic models of gentamicin in paediatric patients. J Clin Pharm Ther 2019; 44: 659-674.
  • 18. Wargo KA, Edwards JD. Aminoglycoside-induced nephrotoxicity. J Pharm Pract 2014; 27(6): 573-577.
  • 19. de Aguiar FC, Solarte AL, Tarradas C, Gómez-Gascón L, Astorga R, Maldonado A, Huerta B. Combined effect of conventional antimicrobials with essential oils and their main components against resistant Streptococcus suis strains. Lett Appl Microbiol. 2019;68(6):562-72.
  • 20. Ghafelehbeshi R, et al. Preparation, physicochemical properties, in vitro evaluation and release behavior of cephalexin-loaded niosomes. Int J Pharm 2019; 5: 569.
  • 21. Lopes E, et al. Epidemiology and antimicrobial resistance of methicillin-resistant Staphylococcus aureus isolates colonizing pigs with different exposure to antibiotics. Plos One 2019; 14(11): 1-10.
  • 22. Xu X, Xu L, Yuan G, Wang Y, Qu Y, Zhou M. Synergistic combination of two antimicrobial agents closing each other’s mutant selection windows to prevent antimicrobial resistance. Sci Rep 2018; 8: 7237-7243.
  • 23. Rahal JJ. Antibiotic combinations: the clinical relevance of synergy and antagonism. Medicine (Baltimore) 1978; 57: 179-195.
  • 24. Aaron SD, Ferris W, Henry DA. Speert DP, MacDonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000; 161: 1206-1212.
  • 25. Nicolas M, Vazquez GF, Paulo A, Caceres G, Silvia M. Carnosic acid acts synergistically with gentamicin in killing methicillin-resistant Staphylococcus aureus clinical isolates. Phytomedicine 2016; 23(12): 1337-1343.
  • 26. Paduszynska MA, Greber KE, Paduszynski W, Sawicki W, Kamysz W. Activity of temporin a and short lipopeptides combined with gentamicin against biofilm formed by Staphylococcusaureus and Pseudomonas aeruginosa. Antibiotics (Basel, Switzerland) 2020; 9(9): 566.
  • 27. Manoraj A, Theyanesam V, Bandara B, Ekanayake A, Liyanapathiana V. Synergistic activity between Triphala and selected antibiotics against drug resistant clinical isolates. BMC Complementary and Alternative Medicine 2019; 19(1): 199.
  • 28. Gil D, Daffine K, Friedman R, Bhushan B, Muratoglu OK, LaPlante K, Oral E. Synergistic antibacterial effects of analgesics and antibiotics against Staphylococcus aureus. Diagnostic Microbiology and Infectious Disease 2020; 96(4): 114967.
  • 29. Feldman M, Smoum R, Mechoulam R, Steinberg D. Potential combinations of endocannabinoid/endocannabinoid-like compounds and antibiotics against methicillin-resistant Staphylococcus aureus. Plos One 2020; 15(4): 1-13.
  • 30. Dall GF, Tsang S, Gwynne PJ, MacKenzie SP, Simpson A, Breusch SJ, Gallahger MP. Unexpected synergistic and antagonistic antibiotic activity against Staphylococcus biofilms. Journal of Antimicrobial Chemotheraphy 2018; 73(7): 1830-1840.
  • 31. Brem J, Berkel V, Zollman SS, Lee D, Gileadi SY, McHugh O, Walsh PJ, Walsh TR, McDonough MA, Schofield CJ. Structural basis of metallo-β-lactamase ınhibition by captopril stereoisomers, Antimicrobial Agents and Chemotheraphy 2015; 60(1): 142-150.
Toplam 31 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Temel Tıp Bilimleri Araştırma Yazıları
Yazarlar

Ayşe Hümeyra Taşkın Kafa 0000-0002-7282-4928

Rukiye Aslan 0000-0001-5843-626X

Yayımlanma Tarihi 30 Mart 2022
Kabul Tarihi 8 Mart 2022
Yayımlandığı Sayı Yıl 2022

Kaynak Göster

AMA Taşkın Kafa AH, Aslan R. Antagonism Between Antibiotics Frequently Used in The Treatment of Staphylococcus aureus Infections and The Hypertensive Drug L-Captopril. CMJ. Mart 2022;44(1):17-21. doi:10.7197/cmj.1064847